BC Extra | Dec 19, 2019
Financial News

Versant’s Pipeline raises $30M series B for regenerative therapies

Aiming to enter the clinic before year end, Versant-backed Pipeline Therapeutics raised $30 million in a series B led by new investor Sectoral Asset Management. Versant Ventures also participated in the round, along with new...
BC Extra | Nov 18, 2019
Clinical News

Karuna quintuples in value as schizophrenia combo clears Phase II bar

Karuna added about $1.8 billion in market cap Monday after a Phase II trial showed its combo therapy targeting muscarinic receptors led to significantly lower psychosis scores in patients with schizophrenia while avoiding the side...
BC Innovations | Nov 18, 2019
Distillery Therapeutics

Targeting muscarinic acetylcholine receptors to treat anemia

DISEASE CATEGORY: Hematology INDICATION: Anemia Muscarinic acetylcholine receptor antagonists could treat anemia associated with myelodysplastic syndrome (MDS), aging or hemolysis. In mice with MDS, a CHRM4 inhibitor tool compound, a CHRM1 inhibitor tool compound or...
BC Extra | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
BC Innovations | Mar 22, 2019
Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
BC Extra | Mar 18, 2019
Financial News

Karuna looks past schizophrenia with $68M series B

Karuna intends to execute on its broader ambitions for lead program KarXT xanomeline/trospium chloride beyond schizophrenia, including development in at least two new indications, after raising $68 million in series B funding. By late 2019,...
BC Innovations | Oct 31, 2018
Distillery Therapeutics

Neurology

INDICATION: Addiction Rat studies suggest M1 muscarinic receptor (CHRM1)-based chemogenetic inhibition of the prelimbic paraventricular thalamic nucleus pathway could help treat cocaine addiction. The system for chemogenetically inhibiting the pathway is initiated by bilateral injection...
BC Innovations | Sep 26, 2018
Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest antagonizing the muscarinic receptor CHRM1 could help treat white matter injury. In a mouse model of neonatal chronic hypoxia-induced white matter injury, CHRM1 knockout in oligodendrocyte precursor cells increased axon...
BC Week In Review | Sep 21, 2018
Clinical News

Sosei, Allergan to delay trials of dementia candidate

Sosei Group Corp. (Tokyo:4565) and partner Allergan plc (NYSE:AGN) have suspended clinical development of neurodegenerative candidate HTL0018318 to investigate a toxicity signal -- a rare tumor -- found in a non-human primate treated with the...
BC Extra | Sep 18, 2018
Clinical News

Sosei, Allergan to delay trials of dementia candidate

Sosei Group Corp. (Tokyo:4565) and partner Allergan plc (NYSE:AGN) have suspended clinical development of neurodegenerative candidate HTL0018318 to investigate a toxicity signal -- a rare tumor -- found in a non-human primate treated with the...
Items per page:
1 - 10 of 82